Yahoo · Aug 13, 2026
BioCardia Inc (BCDA) (Q2 2026) Earnings Call Highlights: Regulatory Wins in Japan and US ...
BioCardia advances toward Japanese Shonin submission and FDA approval pathways while managing cash runway into 2027.
NASDAQ · BCDA
BioCardia, Inc.
Healthcare · Biotechnology
$1.01
Up+$0.04 (+4.44%)
Updated Aug 22, 2026, 10:56 AM
SID Score
4.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 8.58M
- P/E ratio
- -1,087.96
- Dividend yield
- 0.00%
- 52-week range
- $0.75 – $1.80
- Volume
- 82.46K
- Avg. volume
- 598.12K
Price performance
BCDA price history
1M range · 21 trading sessions · Daily adjusted prices
BCDA closed at $1.01 after 21 trading sessions, up 18.81% for the selected period.
- Last close
- $1.01
- Period change
- +18.81%
- Period low
- $0.77
- Period high
- $1.01
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $0.973 | $1.02 | $0.956 | $1.01 | 82.46K |
| Aug 20, 2026 | $1.00 | $1.00 | $0.9501 | $0.9671 | 156.29K |
| Aug 19, 2026 | $0.98 | $1.03 | $0.9266 | $0.991 | 347.28K |
| Aug 18, 2026 | $0.9118 | $0.98 | $0.91 | $0.9754 | 280.62K |
| Aug 17, 2026 | $0.9632 | $0.97 | $0.903 | $0.94 | 180.24K |
| Aug 14, 2026 | $0.95 | $0.98 | $0.9103 | $0.9737 | 158.8K |
| Aug 13, 2026 | $0.88 | $0.9479 | $0.8521 | $0.9289 | 186.47K |
| Aug 12, 2026 | $0.91 | $0.927 | $0.88 | $0.88 | 202.91K |
| Aug 11, 2026 | $0.9766 | $0.9766 | $0.92 | $0.9321 | 112.77K |
| Aug 10, 2026 | $0.98 | $0.987 | $0.9305 | $0.967 | 194.2K |
| Aug 7, 2026 | $0.95 | $0.9879 | $0.9201 | $0.9783 | 196.28K |
| Aug 6, 2026 | $0.92 | $0.9764 | $0.8994 | $0.9496 | 307.71K |
| Aug 5, 2026 | $0.93 | $0.98 | $0.9063 | $0.95 | 805.43K |
| Aug 4, 2026 | $0.89 | $0.95 | $0.855 | $0.9102 | 782.01K |
| Aug 3, 2026 | $0.84 | $0.857 | $0.8163 | $0.8312 | 95.75K |
| Jul 31, 2026 | $0.79 | $0.8249 | $0.79 | $0.8242 | 127.93K |
| Jul 30, 2026 | $0.7858 | $0.8199 | $0.76 | $0.7711 | 94.59K |
| Jul 29, 2026 | $0.79 | $0.8248 | $0.7634 | $0.7737 | 134.89K |
| Jul 28, 2026 | $0.80 | $0.85 | $0.75 | $0.7815 | 226.99K |
| Jul 27, 2026 | $0.90 | $0.90 | $0.80 | $0.8083 | 314.16K |
| Jul 24, 2026 | $0.90 | $0.91 | $0.85 | $0.8501 | 129.82K |
Latest BCDA news
The latest Smart Investors Daily articles mentioning BCDA.
Stock researchCompany · Overview
BCDA research
Overview
Company profile and research snapshot.
Company profile
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 9, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 22, 2025 | HC Wainwright & Co. | Buy | — |
| Dec 18, 2024 | HC Wainwright & Co. | Buy | — |
| Nov 14, 2024 | HC Wainwright & Co. | Buy | — |
| Oct 28, 2024 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 13, 2026
BioCardia, Inc. Q2 2026 Earnings Call Summary
Moby summary of BioCardia, Inc.'s Q2 2026 earnings call
SeekingAlpha · Aug 13, 2026
BioCardia, Inc. (BCDA) Q2 2026 Earnings Call Transcript
BioCardia, Inc. (BCDA) Q2 2026 Earnings Call August 12, 2026 4:30 PM EDTCompany ParticipantsMiranda Benvenuti - Investor Relations ExecutivePeter Altman -...
Yahoo · Aug 12, 2026
BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results
SUNNYVALE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter 2026 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2026 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
